Literature DB >> 35466306

Management of Gastroparesis.

Ting Zheng1, Michael Camilleri1.   

Abstract

Gastroparesis is a gastrointestinal motility disorder characterized by nausea, vomiting, early satiation, postprandial fullness, bloating, and upper abdominal pain. The diagnosis requires documented delay in gastric emptying with an optimal test such as scintigraphy or stable isotope gastric emptying breath test in the absence of mechanical obstruction. The pathophysiologic mechanisms of gastroparesis are multifactorial, including antroduodenal hypomotility, pylorospasm, impaired gastric accommodation, and visceral hypersensitivity. The etiologies of gastroparesis are broad, but the most common subtypes are idiopathic, diabetic, and postsurgical. Less frequent etiologies are neurodegenerative disorder (Parkinson disease), myopathies (scleroderma, amyloidosis), and neoplastic syndrome. Symptoms of gastroparesis can be refractory and challenging to manage, leading to reduced quality of life and significant health care expenditure. This article introduces the epidemiology, clinical presentation, diagnosis, and differential diagnoses of gastroparesis, followed by a focused discussion on its management, including nutritional support, prokinetic and antiemetic agents, and emerging interventions directed at the pylorus. Robust sham-controlled trials are needed to evaluate the long-term efficacy of gastric peroral endoscopic myotomy. A multidisciplinary approach with individualized strategies based on characterization of the patho-physiology is deemed necessary to enhance clinical outcomes.
Copyright © 2021, Gastro-Hep Communications, Inc.

Entities:  

Keywords:  Gastric emptying; gastric accommodation; gastric peroral endoscopic myotomy; nutritional support; prokinetics; visceral hypersensitivity

Year:  2021        PMID: 35466306      PMCID: PMC9021159     

Source DB:  PubMed          Journal:  Gastroenterol Hepatol (N Y)        ISSN: 1554-7914


  92 in total

1.  Laparoscopic pyloroplasty is a safe and effective first-line surgical therapy for refractory gastroparesis.

Authors:  Amber L Shada; Christy M Dunst; Radu Pescarus; Emily A Speer; Maria Cassera; Kevin M Reavis; Lee L Swanstrom
Journal:  Surg Endosc       Date:  2015-08-21       Impact factor: 4.584

Review 2.  A systematic review of the efficacy of domperidone for the treatment of diabetic gastroparesis.

Authors:  Aravind Sugumar; Amanpal Singh; Pankaj Jay Pasricha
Journal:  Clin Gastroenterol Hepatol       Date:  2008-06-04       Impact factor: 11.382

3.  Pharmacological modulation of human gastric volumes demonstrated noninvasively using SPECT imaging.

Authors:  S S Liau; M Camilleri; D Y Kim; D Stephens; D D Burton; M K O'Connor
Journal:  Neurogastroenterol Motil       Date:  2001-12       Impact factor: 3.598

Review 4.  Review article: metoclopramide and tardive dyskinesia.

Authors:  A S Rao; M Camilleri
Journal:  Aliment Pharmacol Ther       Date:  2010-01       Impact factor: 8.171

5.  A small particle size diet reduces upper gastrointestinal symptoms in patients with diabetic gastroparesis: a randomized controlled trial.

Authors:  Eva A Olausson; Stine Störsrud; Håkan Grundin; Mats Isaksson; Stig Attvall; Magnus Simrén
Journal:  Am J Gastroenterol       Date:  2014-01-14       Impact factor: 10.864

Review 6.  Azithromycin for the treatment of gastroparesis.

Authors:  Teresa G Potter; Kenneth R Snider
Journal:  Ann Pharmacother       Date:  2013-02-27       Impact factor: 3.154

7.  Botulinum toxin A for the treatment of delayed gastric emptying.

Authors:  Frank K Friedenberg; Amiya Palit; Henry P Parkman; Alexandra Hanlon; Deborah B Nelson
Journal:  Am J Gastroenterol       Date:  2007-12-05       Impact factor: 10.864

Review 8.  Gastroduodenal Disorders.

Authors:  Vincenzo Stanghellini; Francis K L Chan; William L Hasler; Juan R Malagelada; Hidekazu Suzuki; Jan Tack; Nicholas J Talley
Journal:  Gastroenterology       Date:  2016-05       Impact factor: 22.682

9.  Domperidone in the management of symptoms of diabetic gastroparesis: efficacy, tolerability, and quality-of-life outcomes in a multicenter controlled trial. DOM-USA-5 Study Group.

Authors:  D Silvers; M Kipnes; V Broadstone; D Patterson; E M Quigley; R McCallum; N K Leidy; C Farup; Y Liu; A Joslyn
Journal:  Clin Ther       Date:  1998 May-Jun       Impact factor: 3.393

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.